The Th17 subset is preferentially depleted as compared to the Th1 subset in chronically HIV-infected patients, even after successful antiretroviral therapy. In this study, we have established an in vitro system utilizing primary human CD4 T cell cultures that recapitulates the dramatic loss of Th17 response upon HIV-1 infection that is accompanied with a less profound Th1 decrease. With this experimental system, we showed that blocking viral entry with CCR5 ligands or TAK779 reduced the infection and enhanced Th17 response but not Th1 response. Antiretroviral drug 3TC (lamivudine), given at the time of infection, completely prevented the loss of Th17 and Th1 responses but was ineffective when given after infection was already established. Only when Th17 differentiation cytokines were given along with 3TC to the cultures with established HIV infection was Th17 response fully restored and virus replication kept suppressed. Finally, a significant increase of Th17 response was achieved in peripheral lymphocytes of HIV-infected patients on antiretroviral therapy after treatment with Th17 differentiation cytokines. These data demonstrate the presence of CD4 T cells remaining capable of mounting Th17 response during HIV infection and indicate the potential use of immunotherapeutic modalities to supplement antiretroviral drugs for restoring Th17 response in chronically HIV-infected patients.
Get full access to this article
View all access options for this article.
References
1.
BrenchleyJM, SchackerTW, RuffLEet al.CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med, 2004; 200,6:749–759.
2.
MattapallilJJ, DouekDC, HillB, NishimuraY, MartinM, RoedererM. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature, 2005; 434,7037:1093–1097.
3.
BrenchleyJM, PriceDA, SchackerTWet al.Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med, 2006; 12,12:1365–1371.
4.
GosselinA, MonteiroP, ChomontNet al.Peripheral blood CCR4+CCR6+ and CXCR3+CCR6+CD4+ T cells are highly permissive to HIV-1 infection. J Immunol, 2010; 184,3:1604–1616.
5.
BrenchleyJM, PaiardiniM, KnoxKSet al.Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood, 2008; 112,7:2826–2835.
6.
RomagnaniS. The Th1/Th2 paradigm. Immunol Today, 1997; 18,6:263–266.
7.
AnnunziatoF, CosmiL, SantarlasciVet al.Phenotypic and functional features of human Th17 cells. J Exp Med, 2007; 204,8:1849–1861.
8.
SorooshP, DohertyTA. Th9 and allergic disease. Immunology, 2009; 127,4:450–458.
9.
DuhenT, GeigerR, JarrossayD, LanzavecchiaA, SallustoF. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol, 2009; 10,8:857–863.
MiossecP. IL-17 and Th17 cells in human inflammatory diseases. Microbes Infect, 2009; 11,5:625–630.
12.
Acosta-RodriguezEV, RivinoL, GeginatJet al.Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol, 2007; 8,6:639–646.
13.
IvanovII, McKenzieBS, ZhouLet al.The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell, 2006; 126,6:1121–1133.
14.
KleinschekMA, BonifaceK, SadekovaSet al.Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation. J Exp Med, 2009; 206,3:525–534.
15.
Acosta-RodriguezEV, NapolitaniG, LanzavecchiaA, SallustoF. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol, 2007; 8,9:942–949.
16.
ManelN, UnutmazD, LittmanDR. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol, 2008; 9,6:641–649.
17.
WeiL, LaurenceA, EliasKM, O'SheaJJ. IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner. J Biol Chem, 2007; 282,48:34605–34610.
18.
LiangSC, TanXY, LuxenbergDPet al.Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med, 2006; 203,10:2271–2279.
19.
OuyangW, KollsJK, ZhengY. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity, 2008; 28,4:454–467.
20.
KlattNR, BrenchleyJM. Th17 cell dynamics in HIV infection. Curr Opin HIV AIDS, 2010; 5,2:135–140.
21.
MehandruS, PolesMA, Tenner-RaczKet al.Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection. PLoS Med, 2006; 3,12:e484.
22.
MacalM, SankaranS, ChunTWet al.Effective CD4+ T-cell restoration in gut-associated lymphoid tissue of HIV-infected patients is associated with enhanced Th17 cells and polyfunctional HIV-specific T-cell responses. Mucosal Immunol, 2008; 1,6:475–488.
23.
FavreD, LedererS, KanwarBet al.Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection. PLoS Pathog, 2009; 5,2:e1000295.
24.
CecchinatoV, TrindadeCJ, LaurenceAet al.Altered balance between Th17 and Th1 cells at mucosal sites predicts AIDS progression in simian immunodeficiency virus-infected macaques. Mucosal Immunol, 2008; 1,4:279–288.
25.
ArthosJ, CicalaC, MartinelliEet al.HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol, 2008; 9,3:301–309.
26.
KaderM, WangX, PiatakMet al.Alpha4(+)beta7(hi)CD4(+) memory T cells harbor most Th-17 cells and are preferentially infected during acute SIV infection. Mucosal Immunol, 2009; 2,5:439–449.
27.
KaderM, BixlerS, PiatakM, LifsonJ, MattapallilJJ. Anti-retroviral therapy fails to restore the severe Th-17: Tc-17 imbalance observed in peripheral blood during simian immunodeficiency virus infection. J Med Primatol, 2009; 38,Suppl 1:32–38.
28.
FavreD, MoldJ, HuntPWet al.Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med, 2010; 2,32:32ra36.
29.
SwinglerS, MannA, JacqueJet al.HIV-1 Nef mediates lymphocyte chemotaxis and activation by infected macrophages. Nat Med, 1999; 5,9:997–103.
30.
JacototE, RavagnanL, LoefflerMet al.The HIV-1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore. J Exp Med, 2000; 191,1:33–46.
31.
LiCJ, FriedmanDJ, WangC, MetelevV, PardeeAB. Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein. Science, 1995; 268,5209:429–431.
32.
BandaNK, BernierJ, KuraharaDKet al.Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis. J Exp Med, 1992; 176,4:1099–1106.
33.
RaffatelluM, SantosRL, VerhoevenDEet al.Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut. Nat Med, 2008; 14,4:421–428.
34.
GornyMK, WilliamsC, VolskyBet al.Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades. J Virol, 2002; 76,18:9035–9045.
35.
KaurG, TuenM, VirlandDet al.Antigen stimulation induces HIV envelope gp120-specific CD4(+) T cells to secrete CCR5 ligands and suppress HIV infection. Virology, 2007; 369,1:214–225.
36.
CocchiF, DeVicoAL, Garzino-DemoA, AryaSK, GalloRC, LussoP. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science, 1995; 270,5243:1811–1815.
37.
Garzino-DemoA, MossRB, MargolickJBet al.Spontaneous and antigen-induced production of HIV-inhibitory beta-chemokines are associated with AIDS-free status. Proc Natl Acad Sci USA, 1999; 96,21:11986–11991.
38.
El HedA, KhaitanA, KozhayaLet al.Susceptibility of human Th17 cells to human immunodeficiency virus and their perturbation during infection. J Infect Dis, 2010; 201,6:843–854.
39.
BabaM, NishimuraO, KanzakiNet al.A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA, 1999; 96,10:5698–5703.
40.
RobbinsPA, RoderiquezGL, PedenKW, NorcrossMA. Human immunodeficiency virus type 1 infection of antigen-specific CD4 cytotoxic T lymphocytes. AIDS Res Hum Retroviruses, 1998; 14,16:1397–1406.
41.
AbdelwahabSF, CocchiF, BagleyKCet al.HIV-1-suppressive factors are secreted by CD4+ T cells during primary immune responses. Proc Natl Acad Sci USA, 2003; 100,25:15006–15010.
42.
GrantRM, LamaJR, AndersonPLet al.Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med, 2010; 363,27:2587–2599.
43.
AlfanoM, CrottiA, VicenziE, PoliG. New players in cytokine control of HIV infection. Curr HIV/AIDS Rep, 2008; 5,1:27–32.
44.
JacobsonEL, PilaroF, SmithKA. Rational interleukin 2 therapy for HIV positive individuals: Daily low doses enhance immune function without toxicity. Proc Natl Acad Sci USA, 1996; 93,19:10405–10410.
45.
BolestaE, KowalczykA, WierzbickiAet al.Increased level and longevity of protective immune responses induced by DNA vaccine expressing the HIV-1 Env glycoprotein when combined with IL-21 and IL-15 gene delivery. J Immunol, 2006; 177,1:177–191.
46.
SeretiI, DunhamRM, SpritzlerJet al.IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood, 2009; 113,25:6304–6314.
47.
MastroianniCM, d'EttorreG, ForcinaG, VulloV. Teaching tired T cells to fight HIV: Time to test IL-15 for immunotherapy?Trends Immunol, 2004; 25,3:121–125.
48.
LevyY, DurierC, KrzysiekRet al.Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: A randomized controlled trial. AIDS, 2003; 17,3:343–351.
49.
AbramsD, LevyY, LossoMHet al.Interleukin-2 therapy in patients with HIV infection. N Engl J Med, 2009; 361,16:1548–1559.
50.
NdhlovuLC, SinclairE, EplingLet al.IL-2 immunotherapy to recently HIV-1 infected adults maintains the numbers of IL-17 expressing CD4+ T (T(H)17) cells in the periphery. J Clin Immunol, 2010; 30,5:681–692.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
